

Commercial Medicines Unit

NHS England and NHS Improvement

2nd Floor

Rutland House

Runcorn

Cheshire

WA7 2ES

07730379574

philip.grieve@nhs.net

3 February 2020

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |

**Invitation to offer for NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies – East of England, London and South East Coast**

**Offer reference number: CM/PHS/19/5580**

**Period of framework agreement: 1 July 2020 – 30 June 2021 with options to extend up to a further 36 months. Total maximum framework agreement including extension options will be no more than 48 months**

The NHS Commissioning Board (Operating Under the Name of NHS England) (‘Authority’) invites offers for the above mentioned goods and/or services as defined in Document No.03 Framework Agreement and Terms and Conditions. Offers shall be made subject to the terms of:

Document No.01 This covering letter

Document No.02 Terms of offer

Document No.03 Framework Agreement and Terms and Conditions

Document No.04a Specification

Document No.04b Management Information Schedule

Document No.04c Management Information Schedule - Template

Document No.04d Participating Authorities

Document No.04e Standardised product specifications

Document No.05a Offer Schedule

Document No.05b Specification response

Document No.05c Award methodology and criteria

Document No.06 Form of Offer

Document No.07 Confidential Information Schedule

all of which constitute this Invitation to offer.

NHS England and NHS Improvement

If any of the documents constituting the Invitation to offer is missing please contact the undersigned immediately via the Bravosolution messaging portal.

The Authority does not bind itself to accept the lowest offer or any offer at all and reserves the right to accept an offer either in whole or in part, each item being for this purpose treated as offered separately. The Authority reserves the right to conclude a framework agreement for the supply of the goods and/or services with more than one Offeror.

I would like to draw your attention to the following important points when completing and submitting your offer:

1. All offers must be written in English.

2. All offers must be submitted subject to and in accordance with the documentation comprising the Invitation to offer. Save where the Offerors are instructed to provide information, the documentation comprising the Invitation to offer must not be amended in any way.

3. All offers must be loaded onto the Commercial Medicines Unit’s eTendering portal <https://nhsengland.bravosolution.co.uk/web/login.html>

4. Offers must be open for 90 days.

5. Offers must be fully completed and available on the designated website no later than **1300hrs on 9 March 2020**

I must also draw your attention to the enclosed Form of offer where all the requirements for completing and submitting an offer can be found. Failure to comply with these instructions may result in your offer being rejected.

I hope that the above instructions are clear but please contact the undersigned via the Bravosolution messaging portal if there is anything you wish to clarify.

Yours faithfully

Philip Grieve

Operations Adviser and Developing Commercial Practitioner